Skip to main content

Advertisement

Table 2 Summary of study population for all entered patients

From: A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia

Analysis Population PBO n (%) a LY40 n (%) a LY80 n (%) a RIS n (%) a Total n (%) a
Randomized Patients N = 295 N = 293 N = 282 N = 143 N = 1013
Completed 171 (58.0) 143 (48.8) 129 (45.7) 96 (67.1) 539 (53.2)
ITT Patients in the Overall Population 295 (100.0) 292 (99.7) 280 (99.3) 142 (99.3) 1009 (99.6)
Completed 171 (58.0) 143 (48.8) 129 (45.7) 96 (67.1) 539 (53.2)
Efficacy-Evaluable ITT Patients in the Overall Population 267 (90.5) 267 (91.1) 253 (89.7) 132 (92.3) 919 (90.7)
Completed 154 (52.2) 136 (46.4) 116 (41.1) 90 (62.9) 496 (49.0)
ITT Patients in the Predefined Subpopulation 211 (71.5) 210 (71.7) 195 (69.1) 98 (68.5) 714 (70.5)
Completed 120 (40.7) 107 (36.5) 83 (29.4) 65 (45.5) 375 (37.0)
Efficacy-Evaluable ITT Patients in the Predefined Subpopulation 195 (66.1) 189 (64.5) 176 (62.4) 93 (65.0) 653 (64.5)
Completed 111 (37.6) 101 (34.5) 73 (25.9) 61 (42.7) 346 (34.2)
  1. aPercentages were calculated based on all randomized patients per group.
  2. Abbreviations: ITT intent-to-treat, N/n number of patients.
  3. Groups: PBO = placebo; LY40 = LY2140023 monohydrate 40 mg; LY80 = LY2140023 monohydrate 80 mg; RIS = risperidone.